Publications by authors named "Nigel Parr"

Claim this Profile
I
Image intensifier-guided transperineal prostate biopsy for patients without a rectum: novel technique.
Daniel P McNicholas, Nigel J Parr

BJU Int· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing color cues of development, breeding status and reproductive condition in captive golden lion tamarins (Leontopithecus rosalia).
Lais A A Moreira, Carrie Merrigan-Johnson, Laura Fetherstonhaugh, Nigel A Parr, James P Higham

Am J Primatol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 and preclinical profiling of ESM-HDAC391, a myeloid-targeted histone deacetylase inhibitor, shows enhanced pharmacology and monocytopaenia.
Rebecca C Furze, Judit Molnar, Nigel J Parr, Faiz Ahmad, Yvette Henry

Br J Clin Pharmacol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Novel Bromodomain and Extra Terminal Domain (BET) Protein Inhibitor, I-BET282E, Suitable for Clinical Progression.
Katherine L Jones, Dominic M Beaumont, Sharon G Bernard, Rino A Bit, Simon P Campbell, Nigel Parr

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Guidance for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from an expert group.
Janet E Brown, Catherine Handforth, Juliet E Compston, William Cross, Nigel Parr

J Bone Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based optimisation of orally active & reversible MetAP-2 inhibitors maintaining a tight 'molecular budget'.
David J Hirst, Martin Brandt, Gordon Bruton, Erica Christodoulou, Leanne Cutler, Nigel Parr

Bioorg Med Chem Lett· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
Sarina A Piha-Paul, Christine L Hann, Christopher A French, Sophie Cousin, Irene Braña, Nigel J Parr

JNCI Cancer Spectr· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Experience of Modified Transperineal Template Guided Saturation Biopsy Under General Anaesthesia and without Prophylactic Catheterisation.
Debashis Sarkar, Kingsley Ekwueme, Nigel Parr

Urol Int· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of quinoline based single-ligand human H and H receptor antagonists.
Panayiotis A Procopiou, Rachael A Ancliff, Paul M Gore, Ashley P Hancock, Simon T Hodgson, Nigel A Parr

Bioorg Med Chem Lett· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamic sentinel lymph node biopsy for penile cancer: a comparison between 1- and 2-day protocols.
Panagiotis Dimopoulos, Panagiotis Christopoulos, Sam Shilito, Zara Gall, Brian Murby, Nigel Parr

BJU Int· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Sarah Picaud, Oleg Fedorov, Angeliki Thanasopoulou, Katharina Leonards, Katherine Jones, Nigel Parr

Cancer Res· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of Novel Indazoles as Highly Potent and Selective Inhibitors of Phosphoinositide 3-Kinase δ for the Treatment of Respiratory Disease.
Kenneth Down, Augustin Amour, Ian R Baldwin, Anthony W J Cooper, Angela M Deakin, Nigel J Parr

J Med Chem· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The treatment of penile carcinoma in situ (CIS) within a UK supra-regional network.
Marc Lucky, Kusuma V R Murthy, Beverley Rogers, Stephen Jones, Maurice W Lau, Nigel J Parr

BJU Int· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radical cystectomy and pelvic lymphadenectomy with ileal conduit urinary diversion and abdominal wall reconstruction: an interesting case of multidisciplinary management.
Stratos S Sofos, Ciaran J Walsh, Nigel J Parr, Kevin Hancock

Int Med Case Rep J· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRI use with artificial erection in cases of painful erections.
Marc A Lucky, Luke A McGuinness, Michael S Floyd, Nigel J Parr

Can Urol Assoc J· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Should centralized histopathological review in penile cancer be the global standard?
Vincent Tang, Laurence Clarke, Zara Gall, Jonathan H Shanks, Daisuke Nonaka, Nigel J Parr

BJU Int· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.
Anastasia Wyce, Gopinath Ganji, Kimberly N Smitheman, Chun-Wa Chung, Susan Korenchuk, Nigel Parr

PLoS One· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A coprological survey of parasites in white-faced capuchins (Cebus capucinus) from Sector Santa Rosa, ACG, Costa Rica.
Nigel A Parr, Linda M Fedigan, Susan J Kutz

Folia Primatol (Basel)· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
Aristeidis Chaidos, Valentina Caputo, Katerina Gouvedenou, Binbin Liu, Ilaria Marigo, Nigel J Parr

Blood· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
Olivier Mirguet, Romain Gosmini, Jérôme Toum, Catherine A Clément, Mélanie Barnathan, Nigel Parr

J Med Chem· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transperineal template-guided saturation biopsy using a modified technique: outcome of 270 cases requiring repeat prostate biopsy.
Kingsley Ekwueme, Helen Simpson, Hani Zakhour, Nigel J Parr

BJU Int· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parr and colleagues' response to Tang and colleagues.
Nigel J Parr, Marc A Lucky, Beverly Rogers

BMJ· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The twisted diversion: a paralyzing complication.
Kenneth Hiew, Richard Glendinning, Nigel Parr, Manal Kumar

J Surg Case Rep· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective inhibition of CD4+ T-cell cytokine production and autoimmunity by BET protein and c-Myc inhibitors.
Hozefa S Bandukwala, John Gagnon, Susan Togher, Jason A Greenbaum, Edward D Lamperti, Nigel J Parr

Proc Natl Acad Sci U S A· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer.
Vivek K Wadhwa, Robin Weston, Nigel J Parr

BJU Int· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis